MiNK Therapeutics, INKT is showing recent insider trading activity. Public SEC records indicate that INC AGENUS recently Bought $45,016 worth of shares on 2 weeks ago. With that said, our editors here at politicsandwallstreet.com, are adding INKT to our watchlist to see if this momentum continues.
Based on this transaction and a few others from Corporate Insiders of INKT that Sold 20,488,628 worth of shares in the last 3 months, the Insider Confidence level of MiNK Therapeutics is trending Down.
Since these insiders have unique insights into what's happening at MiNK Therapeutics, this might serve as an indicator of where it is headed.
Here is a list of the latest insider activity for INKT:
In addition, TradingView issued a sell rating for INKT over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook.
Mayank Mamtani
Here is a bit more on MiNK Therapeutics, INKT but please do your own research.
INKT Summary: MiNK Therapeutics Inc. is a clinical stage biotechnology company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T cell therapies to treat cancer and other immune-mediated diseases. MiNK Therapeutics Inc. is headquartered in New York.
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to INKT, you should consider joining TipRanks.com.
PoliticsAndWallStreet.com
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================
Based on this transaction and a few others from Corporate Insiders of INKT that Sold 20,488,628 worth of shares in the last 3 months, the Insider Confidence level of MiNK Therapeutics is trending Down.
Since these insiders have unique insights into what's happening at MiNK Therapeutics, this might serve as an indicator of where it is headed.
Here is a list of the latest insider activity for INKT:
- INC AGENUS - 10 percent owner, Bought $45,016 worth of shares on 2 weeks ago
- INC AGENUS - 10 percent owner, Bought $18,570 worth of shares on 2 weeks ago
- INC AGENUS - 10 percent owner, Bought $262,908 worth of shares on 2 weeks ago
- INC AGENUS - 10 percent owner, Bought $33,348 worth of shares on 4 months ago
In addition, TradingView issued a sell rating for INKT over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook.
Mayank Mamtani
Here is a bit more on MiNK Therapeutics, INKT but please do your own research.
INKT Summary: MiNK Therapeutics Inc. is a clinical stage biotechnology company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T cell therapies to treat cancer and other immune-mediated diseases. MiNK Therapeutics Inc. is headquartered in New York.
- Recent Last Price: $1.25
- Price Change: -$0.07, -5.3%
- Yearly Gain: -46.77%
- Market Cap: $44.52M
- P/E Ratio: -1.725
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to INKT, you should consider joining TipRanks.com.
PoliticsAndWallStreet.com
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================
